Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
DEPO's Cash to Debt is ranked higher than
94% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. DEPO: No Debt )
DEPO' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: No Debt

Equity to Asset 0.39
DEPO's Equity to Asset is ranked higher than
53% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. DEPO: 0.39 )
DEPO' s 10-Year Equity to Asset Range
Min: -2.63   Max: 0.97
Current: 0.39

-2.63
0.97
Interest Coverage 1.73
DEPO's Interest Coverage is ranked lower than
53% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. DEPO: 1.73 )
DEPO' s 10-Year Interest Coverage Range
Min: 1.73   Max: 9999.99
Current: 1.73

1.73
9999.99
F-Score: 4
Z-Score: 3.21
M-Score: 0.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 34.45
DEPO's Operating margin (%) is ranked higher than
98% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. DEPO: 34.45 )
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91   Max: 72.49
Current: 34.45

-12972.91
72.49
Net-margin (%) 35.53
DEPO's Net-margin (%) is ranked higher than
98% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. DEPO: 35.53 )
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35   Max: 75.05
Current: 35.53

-14964.35
75.05
ROE (%) 60.56
DEPO's ROE (%) is ranked higher than
99% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. DEPO: 60.56 )
DEPO' s 10-Year ROE (%) Range
Min: -1132.2   Max: 539.95
Current: 60.56

-1132.2
539.95
ROA (%) 22.88
DEPO's ROA (%) is ranked higher than
98% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. DEPO: 22.88 )
DEPO' s 10-Year ROA (%) Range
Min: -201.37   Max: 73.87
Current: 22.88

-201.37
73.87
ROC (Joel Greenblatt) (%) 939.64
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. DEPO: 939.64 )
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2396.53   Max: 7997.51
Current: 939.64

-2396.53
7997.51
Revenue Growth (%) 15.60
DEPO's Revenue Growth (%) is ranked higher than
81% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. DEPO: 15.60 )
DEPO' s 10-Year Revenue Growth (%) Range
Min: -69.7   Max: 420.5
Current: 15.6

-69.7
420.5
EBITDA Growth (%) 46.00
DEPO's EBITDA Growth (%) is ranked higher than
94% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. DEPO: 46.00 )
DEPO' s 10-Year EBITDA Growth (%) Range
Min: -55.8   Max: 84.2
Current: 46

-55.8
84.2
EPS Growth (%) 120.50
DEPO's EPS Growth (%) is ranked higher than
99% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. DEPO: 120.50 )
DEPO' s 10-Year EPS Growth (%) Range
Min: -59.5   Max: 180.9
Current: 120.5

-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

DEPO Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q4 2013

DEPO Guru Trades in Q4 2013

Jim Simons 129,338 sh (New)
Paul Tudor Jones 19,853 sh (New)
Steven Cohen 1,867,300 sh (New)
» More
Q1 2014

DEPO Guru Trades in Q1 2014

Paul Tudor Jones 63,632 sh (+220.52%)
Jim Simons Sold Out
Steven Cohen 17,403 sh (-99.07%)
» More
Q2 2014

DEPO Guru Trades in Q2 2014

Joel Greenblatt 937,085 sh (New)
George Soros 75,600 sh (New)
Paul Tudor Jones 40,112 sh (-36.96%)
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.16%$10.57 - $14.37 $ 14.7115%937085
George Soros 2014-06-30 New Buy0.01%$10.57 - $14.37 $ 14.7115%75600
Joel Greenblatt 2012-06-30 Sold Out 0.01%$4.97 - $6.6 $ 14.71159%0
Daniel Loeb 2011-09-30 Sold Out 0.6154%$5 - $8.74 $ 14.71122%0
Joel Greenblatt 2011-09-30 Add 48.97%$5 - $8.74 $ 14.71122%15244
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 10.90
DEPO's P/E(ttm) is ranked higher than
98% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. DEPO: 10.90 )
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36   Max: 121.85
Current: 10.9

2.36
121.85
P/B 4.80
DEPO's P/B is ranked higher than
64% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. DEPO: 4.80 )
DEPO' s 10-Year P/B Range
Min: 2   Max: 48.18
Current: 4.8

2
48.18
P/S 3.90
DEPO's P/S is ranked higher than
70% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. DEPO: 3.90 )
DEPO' s 10-Year P/S Range
Min: 1.38   Max: 530
Current: 3.9

1.38
530
EV-to-EBIT 8.21
DEPO's EV-to-EBIT is ranked higher than
97% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. DEPO: 8.21 )
DEPO' s 10-Year EV-to-EBIT Range
Min: 0.4   Max: 130
Current: 8.21

0.4
130
Shiller P/E 62.40
DEPO's Shiller P/E is ranked higher than
78% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 97.53 vs. DEPO: 62.40 )
DEPO' s 10-Year Shiller P/E Range
Min: 21.62   Max: 123.75
Current: 62.4

21.62
123.75
Current Ratio 2.70
DEPO's Current Ratio is ranked higher than
76% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. DEPO: 2.70 )
DEPO' s 10-Year Current Ratio Range
Min: 0.57   Max: 56
Current: 2.7

0.57
56
Quick Ratio 2.63
DEPO's Quick Ratio is ranked higher than
80% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. DEPO: 2.63 )
DEPO' s 10-Year Quick Ratio Range
Min: 0.57   Max: 56
Current: 2.63

0.57
56

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.24
DEPO's Price/Tangible Book is ranked higher than
61% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. DEPO: 8.24 )
DEPO' s 10-Year Price/Tangible Book Range
Min: 2.54   Max: 87
Current: 8.24

2.54
87
Price/DCF (Projected) 12.08
DEPO's Price/DCF (Projected) is ranked higher than
74% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.71 vs. DEPO: 12.08 )
DEPO' s 10-Year Price/DCF (Projected) Range
Min: 1.18   Max: 335
Current: 12.08

1.18
335
Price/Median PS Value 1.08
DEPO's Price/Median PS Value is ranked higher than
80% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. DEPO: 1.08 )
DEPO' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 109.25
Current: 1.08

0.42
109.25
Price/Graham Number 1.97
DEPO's Price/Graham Number is ranked higher than
85% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.69 vs. DEPO: 1.97 )
DEPO' s 10-Year Price/Graham Number Range
Min: 0.61   Max: 7.48
Current: 1.97

0.61
7.48
Earnings Yield (Greenblatt) 12.00
DEPO's Earnings Yield (Greenblatt) is ranked higher than
94% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. DEPO: 12.00 )
DEPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 251.9
Current: 12

0.8
251.9
Forward Rate of Return (Yacktman) 0.46
DEPO's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. DEPO: 0.46 )
DEPO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -27.2   Max: 5.3
Current: 0.46

-27.2
5.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany
Depomed, Inc. was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company that focuses on pain and other conditions and diseases of the central nervous system. Its products line encompasses Gralise, Zipsor, Glumetza, Janumet XR, and Proquin XR, among others. The core products comprises of Gralise, a once-daily product for the management of postherpetic neuralgia, and Zipsor liquid filled capsules, a product for the treatment of mild to moderate acute pain. It also has a portfolio of royalty and milestone producing assets based on its proprietary drug delivery technologies. A part of it is Glumetza, a once-daily treatment for adults with type 2 diabetes which is licensed and commercialized in the United States. It also has license and development arrangements for Acuform gastroretentive drug delivery technology with Covidien, Ltd., Boehringer Ingelheim International GMBH, Ironwood Pharmaceuticals, Inc., Merck & Co., Inc., Janssen Pharmaceutica N.V. and Janssen Pharmaceuticals, Inc. Further, it has two product candidates in clinical development, Serada and DM-1992. The Company derives revenues from the sale of its products, and from license fees, milestones and royalties earned on license agreements, as well as collaborative arrangements.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Reports Second Quarter 2009 Financial Results Jul 30 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
OxyContin, Cialis Makers Dodge Court to Beat Patent Suits Oct 02 2014
Accelerated selling means it’s time to move to cash Sep 30 2014
DEPOMED INC Files SEC form 8-K, Other Events Sep 17 2014
DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Sep 09 2014
DEPOMED INC Files SEC form 8-K, Other Events Sep 05 2014
Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for... Sep 05 2014
DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 04 2014
Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021 Sep 04 2014
DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 02 2014
Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 Sep 02 2014
Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference Aug 25 2014
Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference Aug 25 2014
DEPOMED INC Files SEC form 8-K, Other Events Aug 21 2014
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs Aug 19 2014
Why DepoMed (DEPO) Stock Is Gaining Today Aug 19 2014
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 Aug 19 2014
DEPOMED INC Financials Aug 15 2014
DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2014
Depomed Inc Earnings Call scheduled for 4:30 pm ET today Aug 06 2014
Depomed Reports Second Quarter 2014 Financial Results Aug 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK